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Abstract
Background and aims: Previous studies have suggested an increasing use of complementary and
alternative medicine (CAM) in patients with inflammatory bowel disease (IBD). Furthermore, a
significant number of IBD patients fail to comply with treatment. The aim of our study was to
evaluate the prevalence of non-adherence and the use of CAM in Hungarian patients with IBD.
Methods: A total of 655 consecutive IBD patients (CD: 344, age: 38.2 [SD 12.9]years; UC: 311,
age: 44.9 [15.3]years) were interviewed during the specialist visit by self-administered
questionnaire including demographic and disease-related data as well as items analyzing the
extent of non-adherence and CAM use. Patients taking more than 80% of each prescribed
medication were classified as adherent.nt of Medicine, Semmelweis University, Koranyi st. 2/A, H-1083 Hungary. Tel.: +36 1 2100278; fax: +36
e.hu (P.L. Lakatos).
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demographic factors and disease pheResults: The overall rate of self-reported non-adherence (CD: 20.9%, UC: 20.6%) and CAM (CD:
31.7%, UC: 30.9%) use did not differ between Crohn's disease (CD) and ulcerative colitis (UC). The
most common causes of non-adherence were: forgetfulness (47.8%), too many/unnecessary pills
(39.7%), being afraid of side effects (27.9%) and too frequent dosing. Most common forms of CAM
were herbal tea (47.3%), homeopathy (14.6%), special diet (12.2%), and acupuncture (5.8%). In
CD, disease duration, date of last follow-up visit, educational level and previous surgeries were
predicting factors for non-adherence. Alternative medicine use was associated in both diseases
with younger age, higher educational level, and immunosuppressant use. In addition, CAM use in
UC was more common in females and in patients with supportive psychiatric/psychological
therapy.
Conclusions: Non-adherence and CAM use is common in patients with IBD. Special attention
should be paid to explore the identified predictive factors during follow-up visits to improve
adherence to therapy and improving patient–doctor relationship.
© 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.L, et al, Association of adheren
notype in patients..., Journal1. IntroductionInflammatory bowel disease (IBD) is a multifactorial entity
with both, genetic and environmental factors contributing to
disease pathogenesis.1 Worldwide, the incidence rates for
IBD vary from 0.5 to 24.5 per 100,000 person-years,2 with the
majority of patients being disabled during various parts of
their lives. This characteristic may also suggest poor
adherence (i.e., a percentage of the prescribed doses is
not taken) outside the clinical trial settings.3,4
Treatment of IBD can involve several medications with
varying regimens, dietary modifications, and potentially,
surgery, depending on symptoms, severity of illness, and
response to treatment. Adherence to the pharmacological
treatment is a complex process, where the doctor–patient
relationship, treatment regimen and other disease-related
factors play key roles. The undesirable side effects of some
medications (e.g., weight gain, cushingoid appearance, and
immune suppression) and the complex treatment regimens
for IBD patients (e.g., varying dosing schedules and pill
quantities for each medication) are likely to disrupt
adherence and the effective management of this condition.
These data are consistent with the hypothesis that many
patients engage in an implicit cost–benefit analysis in which
beliefs about the necessity of their medication are weighed
against concerns about the potential adverse effects of
taking it and that these beliefs are related to medication
adherence, as in other chronic conditions.5
Research on adherence in IBD is limited. Studies in adults
have revealed medication non-adherence prevalence rates
ranging from 15 to 72%.3,4,6–8 For example, a cross-sectional
study of US outpatients with quiescent ulcerative colitis (UC)
found that only 40% were adherent to maintenance therapy
with mesalazine (mesalamine).3 In the UK, approximately
15% of patients fail to even redeem prescriptions at the
pharmacy.9 Moreover, treatment non-adherence rates may
vary considerably between countries. In Europe, a survey of
203 IBD patients revealed self-reported non-adherence rates
ranging from 13% in France, to 26% in Italy, 33% in the UK and
46% in Germany. The overall non-adherence rate was 29%
across Europe,10 where non-adherence was defined as taking
b80% of the prescribed medication. Similarly high rates of
non-adherence were reported from Eastern Europe. Overall,ce
ofthe intentional non-adherence rate was reported by 38.9% of
patients, and 18.6% of the patients discontinued therapy at
least once.4 In a Canadian study, UC diagnosis was associated
with a higher risk for non-adherence (OR: 4.42).11
Suggested predictors of non-adherence include age, since
younger patients tend to be less adherent than older
patients,6,12 gender,3,13 full-time employment,11 educational
level,4,11,14 recent diagnosis,12 drug type, formulation and
dosing regime3,12 and in Crohn's disease (CD) complicated
disease course.8 Moreover, the partnership between patient
and treating physicians are of utmost importance in deter-
miningmedical adherence, where effective patient–physician
dialog is central to promoting patient adherence. Both the
quality and quantity of the visits are important. Sewitch et al.6
found an increased risk of intentional non-adherence to be
associated with being treated by the same physician for more
than 1 year, not scheduling another appointment, and greater
total discordance between the patient and the physician.
Complementary and alternative medicine (CAM) includes
a wide range of practices and therapies outside the realms of
conventional western medicine.15 CAM use is also common
among patients with IBD. The reported rates of CAM use in
IBD have increased from 4–13% observed in the late 1980s16
to 31–68%17,18 almost a decade later. Although these rates
may not be directly comparable with each other due to
differences in the definition of CAM use, they show a clear
trend of increasing CAM use in IBD patients, parallel to the
boom observed in the general population. In general
population surveys, use of CAM was associated with higher
education and income, poorer health status, and a holistic
orientation to health.19 Partly conflictive data are available
in IBD. In a Canadian study,20 CAM use was associated with
more severe disease activity, use of CAM for other purposes,
and a desire for an active role in treatment decisions. CAM
use was also associated with younger age in those with
Crohn's disease, and less confidence in their IBD physician in
those with ulcerative colitis. In contrast, patient's age,
gender, disease diagnosis, or duration of disease were not
predictive of any type of alternative medicine use in a
multicentric study including Canada, Ireland, Sweden and
the US.17 However, no data on the prevalence of and reason
for CAM use are available from Eastern Europe.
The aim of our study was to prospectively evaluate the
prevalence of andpredictors for non-adherenceandCAMuse into therapy and complementary and alternative medicine use with
Crohn's and Colitis (2009), doi:10.1016/j.crohns.2009.11.011
Table 1 Clinical characteristics and demographic data of
patients with inflammatory bowel diseases.
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analyzed the association between medical non-adherence/
CAM use and demographic data and clinical phenotype.CD
(n=344)
UC
(n=311)
Male/female 143/201 158/153
Age (years) 38.2±12.9 44.9±15.3
Duration (years) 8.5±7.6 11.0±8.6
Last follow-up visit by
specialist (months)
6.5±7.5 8.6±9.6
Place of residence
(rural/urban/missing)
83/211/50 92/160/59
Education level (High/
medium/low/missing)
37/179/87/41 54/136/72/49
Familial IBD 1 31 (9.0%) 23 (7.4%)
Location (n) In CD
L1 69 –
L2 114
L3 158
L4 only 3
Maximum extent (n) in UC
Proctitis – 84
Left-sided 123
Extensive 104
Behavior (n)
B1 158 –
B2 95
B3 91
Perianal disease 1 113 (32.8%) –
Current medical therapy
5-ASA use 1 66 (19.2%) 268 (86.2%)
Topical 5-ASA use 1 14 (4.1%) 73 (23.4%)
Steroid use 1 127 (36.9%) 72 (23.1%)
Azathioprine/methotrexate
use 1
197 (57.3%) 85 (27.3%)
Infliximab use 1 39 (11.1) 1 (0.6%)
Surgery/reoperation in CD1 161 (46.8%) /
67 (19.5%)
–
Smoking habits (n)
No 176 217
Yes 98 33
Former 70 61
Location: L1: terminal ileum, L2: colon, L3: ileocolon, L4: upper
gastrointestinal.
Behavior: B1: non-stricturing non-penetrating, B2: stricturing,
B3: penetrating.2. Materials and methods
A total of 655 consecutive IBD patients (CD: 344, males/
females: 143/201, age: 38.2 [SD 12.9]years; UC: 311, males/
females: 158/153, age: 44.9 [SD 15.3]years) were prospec-
tively interviewed during an outpatient specialist visit using
a self-administered questionnaire. Participating centres
were all referral gastroenterology units with a special focus
on IBD. The diagnosis was based on the Lennard–Jones
criteria.21 Age, disease duration, last follow-up visit by a
gastroenterologist, the presence of familial IBD, location,
medical therapy, need for surgery (resections), and smoking
habits, and in CD, disease behavior and perianal involve-
ment, were investigated by reviewing the medical charts by
the physician and completing a questionnaire. In the UC
cohort, there were no post-colectomy patients. The disease
phenotype was determined according to the Montreal
classification.22
The questionnaire included 25 detailed questions regard-
ing demographics and disease-related data as well as items
analyzing the extent of non-adherence and CAM use. Type
(oral vs topical) and frequency of medications prescribed was
recorded as well as magnitude of (30%, 30–50%, 50–80% and
N80% of prescribed medication taken) and reason for both
intentional and non intentional non-adherence to oral or
topical medication for the last 12 months. We did not record
the adherence data for biological therapy, since at the time
of the study, most of the IBD patients received infliximab
(adalimumab was used in only two patients), and biological
exposure in UC was minor. We also recorded the frequency,
type, and reason for CAM use. In addition, frequency and
reason for supportive therapy by a psychiatrist or psychol-
ogist was recorded. Patients taking more than 80% of each
prescribed medicine were classified as adherent. Detailed
clinical phenotypes were determined by reviewing the
medical charts by the treating physician. The clinical data
of the CD and UC patients are presented in Table 1.
The study protocol was approved by the Ethical and
Science Committee of the Ministry of Health (ETT TUKEB, ad
260/PI/2009, ad.8-103/2009-1018EKU). Each patient was
informed of the nature of the study and signed the informed
consent form.PSC: primary sclerosing cholangitis.
1 n (%).2.1. Statistical analysis
Variables were tested for normality using Shapiro Wilk's W
test. T-test with separate variance estimates, χ2-test and
χ2-test with Yates correction were used to evaluate
differences between different subgroups of IBD patients.
Binary logistic regression was used to compare the associa-
tion between clinical, demographic data and non-adherence
or CAM use. Each variable with a p≤0.1 identified in
univariate association testing was included in the binary
logistic regression models. A p value ofb0.05 was considered
as significant. Peter Laszlo Lakatos performed the statistical
analysis using the SPSS15.0 (SPSS Inc, Chicago, IL) software.Please cite this article as: Lakatos PL, et al, Association of adherence
demographic factors and disease phenotype in patients..., Journal of3. Results
3.1. Non-adherence rate and CAM use in patients
with inflammatory bowel disease
The overall rate of self-reported non-adherence and CAM use
was not different between CD and UC (see Fig. 1). The most
common causes of non-adherence were: forgetfulness, too
many/unnecessary pills, being afraid of side effects, and too
complicated administration schedule (Table 2). Most com-
mon forms of CAM were: herbal tea use, homeopathy, andto therapy and complementary and alternative medicine use with
Crohn's and Colitis (2009), doi:10.1016/j.crohns.2009.11.011
Figure 1 Frequency of self-reported non-adherence and
complementary and alternative medicine (cam) use in patients
with inflammatory bowel diseases.
Table 4 Predictive factors for self-reported non-adherence
in patientswith Crohn's disease in univariate analysis (χ2-test).
Factor Non-adherent (%) p value OR (95% CI)
Duration
b10 years 22.4 0.013 –
10–20 years 10.0
N20 years 34.5
Last follow-up visit
b12 months 19.0 0.019 2.13
(1.12–4.05)≥ 12 months 33.3
Educational level (n=303)
Low 35.1 0.026 –
Medium 22.9
High 13.8
Immunosuppressant use
Yes 17.3 0.068 1.63
(0.96–2.75)No 25.3
Previous surgeries
No 25.4 0.003
1 22.3
2 or more 6.0
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of CAM users reported that they use also other forms of CAM
without further explanation. Most common reasons for CAM
use reported by the patients were supplementary therapy in
addition to prescribed conventional medicines (80.5%, 165/
205), having the feeling that medical therapy is not effective
enough (17.5%), to treat side effects of the conventional
medical therapy (6.8%), and the belief that it is more
effective than conventional medical therapy (4.4%).
The overall frequency for seeking supportive therapy from a
psychiatrist or psychologist was similar in both diseases (CD:
13.9% [45/323] and UC 13.5% [37/275]). The most common
motivation for this was inability to deal with the diagnosis and
psychosocial pressure because of the disease in the family or at
work.
3.2. Association between non-adherence, CAM use,
and disease phenotype or demographic data
In CD, non-adherence was associated with disease duration
and in patients with a last follow-up visit beyond one yearTable 2 Reported causes for medical non-adherence
(n=136) in patients with inflammatory bowel diseases.
Frequency
Forgetfulness 47.8%
Too many/unnecessary pills 39.7%
Being afraid of side effects 27.9%
Too frequent dosing 13.9%
Too complicated administration schedule 4.4%
Table 3 Common types of complementary and alternative
medicine use (n=205) in patients with inflammatory bowel
diseases.
Frequency
Herbal tea 47.3%
Homeopathy 14.6%
Special diet 12.2%
Acupuncture 7.8%
Energy transfer 5.8%
Magnetic therapy 1.9%
Please cite this article as: Lakatos PL, et al, Association of adherence
demographic factors and disease phenotype in patients..., Journal of(p=0.019, OR: 2.13, 95% CI: 1.12–4.05, Table 4). In addition,
educational level, previous surgeries, and immunosuppres-
sant use were also associated with non-adherence (Table 4),
but not with disease location, behavior, smoking status,
5-ASA or steroid use. There was also no difference between
patients receiving oral or topical therapy. The number of
concomitant medications was also not predictive of medical
non-adherence. In a logistic regression analysis, the level of
education and previous surgeries were identified as inde-
pendent factors, with a strong tendency for date of last
follow-up visit and immunosuppressant use (Table 5). In
contrast, none of the factors analyzed was associated with
probability of non-adherence in UC.
In both forms of IBD, alternative medicine use was
associated with younger age, higher educational level, and
immunosuppressant use (Table 6). In CD, CAM use was also
more common in patients receiving 5-ASAs, while in UC, it wasTable 5 Logistic regression: predictive factors for self-
reported non-adherence in patients with Crohn's disease.
Factor Coefficient p value OR 95% CI
Disease duration 0.220 0.361 – –
Date of last
follow-up visit
0.638 0.072 1.89 0.96–3.79
Low education level 0.541 0.028 1.72 1.06–2.78
No immunosuppressant
use
0.527 0.075 1.69 0.95–3.03
Previous surgery 0.559 0.011 1.75 1.14–2.69
The coefficient is equivalent to the natural log of the OR;
p value: level of significance; OR: odds ratio; 95% CI: 95%
confidence interval.
to therapy and complementary and alternative medicine use with
Crohn's and Colitis (2009), doi:10.1016/j.crohns.2009.11.011
Table 6 Predictive factors for complementary and
alternativemedicine (CAM) use in patientswith inflammatory
bowel diseases in univariate analysis.
Factor CAM use (%) p value OR (95% CI)
Crohn's disease
Age
b40 years 40.4 b0.001 2.63 (1.59–4.39)
N40 years 20.5
Educational level (n=303)
Low 21.6 0.018* –
Medium 31.8
High 41.4
5-ASA use
Yes 46.2 0.008 2.09 (1.20–3.64)
No 29.1
Immunosuppressant use
Yes 37.5 0.017 1.78 (1.11–2.88)
No 25.2
Ulcerative colitis
Age
b40 years 44.4 b0.001 2.39 (1.45–3.94)
N40 years 25.0
Gender
Females 39.7 0.017 1.82 (1.11–3.00)
Males 26.5
Place of residence (n=252)
Urban 35.7% 0.01 2.47 (1.22–4.94)
Rural 21.2%
Educational level (n=262)
Low 16.7 0.018* –
Medium 33.1
High 38.2
Psychiatric/psychological supportive care (n=275)
Yes 59.5 0.001 3.18 (1.56–6.50)
No 31.6
Immunosuppressant use
Yes 51.3 b0.001 2.90 (1.67–4.96)
No 24.7
Steroid use
Yes 47.1 0.004 2.24 (1.29–3.90)
No 28.4
p calculated by χ2-test or *linear-by-linear association.
Table 7 Logistic regression: predictive factors for
complementary and alternative medicine use in patients
with ulcerative colitis.
Factor Coefficient p value OR 95% CI
Female gender 0.439 0.169 – –
AgeN40 years −0.681 0.036 0.51 0.27–0.96
Urban residency 0.668 0.012 2.07 1.14–3.83
Education level 0.319 0.206 – –
Immunosuppressant use 0.989 0.009 2.69 1.28–5.64
Steroid use 0.549 0.14 – –
Psychiatric/psychological
therapy
1.001 0.023 2.72 1.15–6.45
The coefficient is equivalent to the natural log of the OR; p value:
level of significance; OR: odds ratio; 95%CI: 95% confidence interval.
5Adherence and CAM in IBD
ARTICLE IN PRESSmore common in females, steroid users, and in patients with
additional psychiatric or psychological therapy. In addition,
CAM use in UC was associated with the number of concomitant
medications, gradually increasing from 25.8% in patients
receiving only one medication to 52.4% in patients receiving
three or more different medication types (p=0.004). No other
clinically relevant associations–including drug formulation–
were found in either CD or UC. The number of concomitant
medications was not predictive for CAM use. In addition, there
was no association betweennon-adherent attitude–magnitude
and CAM use (data not shown).
In a multivariate analysis, age (Coefficient: −0.904,
p=0.002, OR: 0.41; 95% CI: 0.23–0.72) and 5-ASA use
(Coefficient: 0.693, p=0.042, OR: 1.99, 95% CI: 1.38–3.89)
were identified as independent predictors for CAM use in CD.Please cite this article as: Lakatos PL, et al, Association of adherence
demographic factors and disease phenotype in patients..., Journal ofHowever, in UC, age, place of residence, immunosuppressant
use, and additional psychiatric/psychological therapy were
identified as independent predictors for CAM use in a logistic
regression analysis (Table 7).4. Discussion
This is one of the first studies to investigate the prevalence
and predictors of medical non-adherence and CAM use in
Eastern Europe. In the present study, the authors found a
relatively high prevalence of self-reported non-adherence
and CAM use in a large Hungarian IBD cohort followed-up at
referral IBD centres. The rate of medical non-adherence
reported in the present study (approx. 21%) is within the
range reported from European centres (29%),10 by using
similar methodology and definition of non-adherence. A
drawback of this method, however, is that it can both under-
and overestimate adherence, and its accuracy depends on
the patient's cognitive abilities, the honesty of replies, as
well as the interviewer's correct interpretation of responses.
The patient may forget doses taken or missed. The most
common causes of non-adherence, as reported by the
patient (e.g., forgetfulness, too many/unnecessary pill,
being afraid of side effects) were similar to that reported
in previous studies.8,11
By using univariate and multivariate analysis, the date of
the last follow-up visit, lower educational level, previous
surgeries, and immunosuppressant use were also associated
with non-adherence in patients with Crohn's disease. In
contrast, a higher education level and full-time employment
were also associated with a non-adherent patient behavior in
some,4 but not all previous studies.8 In a recent Italian
study,12 non-adherence was 43% in patients b40 years old
compared to 34% in those older than 40 years (p=0.041, OR:
1.5, 95% CI: 1.01–2.13). A recent diagnosis and disease
duration shorter than 5 years was also associated with
significantly worse adherence (24% of the patients) than a
longer-standing disease (15% of the patients; p=0.001, OR:
2.1, 95% CI: 1.30–3.39) in the same study. In the present
study, both short and very long disease duration was
associated with higher non-adherence rates. In addition,
we failed to identify the previously reported association
between gender and medical adherence.3,6,23to therapy and complementary and alternative medicine use with
Crohn's and Colitis (2009), doi:10.1016/j.crohns.2009.11.011
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cated disease course in CD was reported by Spanish authors.8
Better adherence was significantly associated with a more
complicated disease course (steroid dependency, steroid
refractoriness, need for infliximab treatment, hospitaliza-
tion, or surgery) in patients with short disease duration.
Similarly, in the present study, a higher number of previous
resection surgeries and need for immunosuppressant therapy
suggesting a more aggressive disease course was associated
with improved self-reported adherence in patients with CD.
In both, CD and UC, active disease was associated with higher
adherence even if steroids were included in the treatment
regimen.6 In contrast, other studies reported low adherence
rate after long-term remission.3,12 Very high non-adherence
rates (74.3%) were reported for azathioprine in CD patients
who were in a long term (N48 months) clinical remission.23
In UC, Kane et al.3 reported by means of a univariate
analysis, the male gender, not being in a relationship, left-
sided disease, and a history of more than four concomitant
medications were negatively associated with adherence.
Conversely, being married, a recent colonoscopy, and
greater extent of disease support adherence. In contrast,
in the present study, none of the factors analyzed were
associated with probability of non-adherence.
Non-adherence to therapy might also be due to the drug
formulation causing discomfort (difficulty in swallowing
tablets or using enemas) or side effects (pain or abdominal
distension, difficulty in retaining enemas). Most studies are
consistent in finding that topical therapy with enemas,
suppositories or foams is more likely to be associated with
non-adherence than oral therapy. In an Italian study,12 topical
therapy with enemas was associated with significantly more
non-adherence (68% of users) than oral therapy (40% of users;
p=0.001, OR: 0.25, 95% CI: 0.11–0.60). In contrast, in the
present study, the use of topical 5-ASAwas not associatedwith
lower adherence rates. Of note, however, only 23.4% of the UC
patients received this form treatment; most of them as
adjunctive therapy with oral 5-ASA.
The association between the type of oral medications and
non-adherence is also complex. Reasons for non-adherence
with oral therapy include multiple daily doses and a high
number of concomitant medications. The undesirable side
effects of some medications (e.g., weight gain, cushingoid
appearance, and immune suppression) and the complex
treatment regimens for IBD patients (e.g., varying dosing
schedules and pill quantities for each medication) are likely
to disrupt adherence and effective management of this
condition. In the study by Kane et al.,3 besides being males,
single and having left-sided disease, non-adherent patients
were statistically more likely to be simultaneously taking
four or more medications (60% vs. 40%). In an Italian study,
the need to take medications during work hours (p=0.001,
OR: 3.5, 95% CI: 2.27–5.26), and multiple daily doses
(p=0.045, OR: 2.8, 95% CI: 0.99–7.70) were significantly
associated with non-adherence in adults.12 Similarly, ado-
lescents whose regimen involved more than one daily
medication administration had more adherence barriers.24
Interestingly, some studies did not report a direct associa-
tion. For example, in the study by Cerveny et al.,4 the non-
adherence rate at any time point was 40% on aminosalicy-
lates, 29% in patients on systemic steroids, and 31% in
patients on immunosuppressants in IBD, supporting thePlease cite this article as: Lakatos PL, et al, Association of adherence
demographic factors and disease phenotype in patients..., Journal ofnotion that adherence is influenced by multiple parallel
factors, including gender, age, disease phenotype, course,
and disease activity. In the present study, we did not find an
association between the drug type, dosing regimen, and
concomitant number of medications and medical adherence
except for the reported better adherence in patients on
immunosuppressants. However, the better adherence in
those patients might be partly secondary to the more
aggressive disease course as highlighted by the higher
surgical need in those patients.
Finally, the partnership between patient and treating
physicians are of utmost importance in determining medical
adherence, where effective patient–physician dialog is
central to promoting patient adherence.12 Sewitch et al.6
found an increased risk for intentional non-adherence to be
associated with being treated by the same physician for more
than 1 year, not scheduling another appointment, and
greater total discordance between the patient and the
physician. Similarly, a last follow-up visit beyond 1 year was
predictive for reduced adherence in the present study.
A limitation of the present study is that the no direct
methods for measuring medication adherence were used.
However, only a limited number of drugs can be monitored in
this manner. In IBD, bioassays measuring 6-thioguanine
nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide
(6-MMPN) levels have been suggested as potentially useful
objective adherence markers for 6-mercaptopurine (6-MP)/
azathioprine (AZA).25,26 The bioavailability and completeness
of absorption of various drugs, as well as the rate of
metabolism and excretion, are factors that make it difficult
to correlate drug concentrations in blood or urine with
adherence. Moreover, the ability of direct methods to identify
non-adherence also depends on the accuracy of the test and
the degree to which the patient was non-adherent before the
urine or blood sample was taken.
The rateof CAMuse (approx. 31%) found in thepresent study
is in concordance with international trends reporting increas-
ing number of CAM users in the average population as well as in
IBD in the last decade.18,20,27 Alternative medicine use was
associated in both diseases with younger age, higher educa-
tional level, and immunosuppressant use, while in UC it was
also associated with gender, number of concomitant medica-
tions, and additional psychiatric or psychological therapy. In
both diseases, age, while in UC, also place of residence,
immunosuppressant use, and additional psychiatric/psycho-
logical therapy were identified as independent predictors for
CAM use in a multivariate analysis.
In a Canadian study,20 CAM use was associated with more
severe disease activity, use of CAM for other purposes, and a
desire for an active role in treatment decisions. CAM use was
also associated with younger age in those with Crohn's
disease, and less confidence in their IBD physician in those
with ulcerative colitis. In contrast, patient age, gender,
disease diagnosis, or duration of disease was not predictive of
any type of alternative medicine use in a multicentre study
including Canada, Ireland, Sweden, and the US.17 Moreover,
in a phone survey study,28 CAM use could not be predicted by
either greater or less hospitalizations, conventional doctor
visits, or GI specific visits. CAM was sought mostly to palliate
pain or diarrhea. Of note, however, rates and predictors may
not be directly comparable with each other due to differ-
ences in the definition of CAM use.to therapy and complementary and alternative medicine use with
Crohn's and Colitis (2009), doi:10.1016/j.crohns.2009.11.011
7Adherence and CAM in IBD
ARTICLE IN PRESSIn conclusion, non-adherence and CAM use is common in
patients with IBD. Special attention should be paid to explore
the identified predictive factors during follow-up visits to
improve adherence to therapy, understand motivation for
CAM use, and improve patient–doctor relationship.Conflict of interest
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